Article

BlephEx introduces medical device for blepharitis

A novel medical device from BlephEx allows physicians to perform a painless, in-office procedure to treat blepharitis-thus relieving patients from the chronic and irritating symptoms of inflammatory lid disease and dry eye.

BlephEx introduces medical device for blepharitis

 

Chicago-A novel medical device from BlephEx allows physicians to perform a painless, in-office procedure to treat blepharitis-thus relieving patients from the chronic and irritating symptoms of inflammatory lid disease and dry eye.

The BlephEx handpiece enables eye-care professionals to reduce scurf, bacterial debris, and the biofilm-thereby improving the overall health of the eyelid, said James Rynerson, MD, president and chief executive officer of BlephEx LLC.

In case you missed it: LASIK Quality of Life Collaboration Project characterizes benefit, burden

The device can save patients hundreds of dollars in the costs of prescription drops, home scrubs, humidity goggles, and artificial tears that mask the symptoms but do not eliminate the cause, according to the company.

Dr. Rynerson explained that the medical device removes the biofilm, completely clearing the lids of the inflammatory exotoxins that accumulate along the margins.

 

BlephEx features a medical grade disposable, micro-sponge that spins along the edge of eyelids and lashes, exfoliating the eyelids. A numbing drop is placed in each eye prior to treatment for increased comfort. Following the 6- to 8-minute, well-tolerated procedure, patients often report a near immediate resolution of the chronic eye irritation associated with blepharitis and an eventual resumption of normal tear production.

 

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.